Highest-materiality recent filing
Total net revenue $42.2M, down 42% YoY due to absence of $25M Recordati upfront payment and generic pressure on U.S. VASCEPA pricing.
Amarin Q1 total revenue up 7% to $45.1M; operating loss narrows 32%; cash flow positive
Total net revenue $45.1M (+7% YoY); U.S. product revenue $35.6M flat; European revenue $4.9M (-9%); ROW $2.8M.
Q4 net loss improved 97% to $(1.2)M ($0.00 per share) from $(48.6)M in Q4 2024.
Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M
Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.
Amarin Q3 net revenue $49.7M (+17% YoY), operating loss narrows 56% to $11.1M
Total net revenue $49.7M, up 17% YoY, driven by US sales rebound and exclusive PBM status.
Amarin Q2 net loss $14.1M; signs European licensing deal with Recordati, plans restructuring
Q2 net loss of $14.1M ($0.03 per share) vs. $1.5M net income in Q2 2024.
Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings
Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.
Amarin Q1 2025 net revenue $42M (-26% YoY); net loss $15.7M, wider than prior year
Total net revenue $42.0M vs $56.5M in Q1 2024, down 26% due to generic competition in U.S.
Amarin regains Nasdaq minimum bid price compliance after ADS ratio change
Received Nasdaq confirmation on April 29, 2025 that bid price averaged ≥$1.00 over 10 consecutive days.
Amarin Q4 revenue $62.3M, net loss $48.6M; announces 1-for-20 ADS reverse split to maintain listing
Q4 total net revenue $62.3M, down 17% YoY; net loss $48.6M vs $5.8M loss in Q4 2023.
Nasdaq granted 180-day extension until May 19, 2025 to meet $1.00 minimum bid price.
Total net revenue $42.3M (-36% YoY); U.S. net product revenue $30.6M (-51%) from generic competition and CVS delisting.
CFO Tom Reilly resigns effective Oct 23, 2024; interim CFO named
Tom Reilly voluntarily resigns as EVP, CFO and Head of Global HR & Finance, effective October 23, 2024, to pursue another opportunity.
Amarin Q2 revenue down 16% to $67.5M; PBM drops VASCEPA coverage; new CEO
Total net revenue $67.5M (-16% YoY); net product revenue $47.5M (-27%) pressured by US generic competition.
Amarin CEO resigns; large PBM to drop Vascepa coverage July 1, affecting 25% of US volume
CEO Pat Holt resigned; Aaron Berg appointed as President & CEO effective June 4, 2024.
Amarin receives Nasdaq deficiency notice over bid price below $1.00 for 30 days
Nasdaq notified Amarin on May 24, 2024 that its ADS closing bid price has been below $1.00 for 30 consecutive business days.
Amarin Q1 revenue $56.5M (-34% YoY); European in-market sales +65% QoQ; GAAP loss $0.02
U.S. net product revenue fell 41% YoY to $48.1M on generic price erosion; gross margin narrowed to 55% from adjusted 70% a year ago.
Amarin shareholders approve $50M share repurchase program and board declassification
Shareholders approved two proposals enabling up to $50M share repurchase; final step is UK High Court approval, expected by end of Q2 2024.
Amarin extends VAZKEPA European patent exclusivity to 2039; defends 2033 patent
EPO granted new VAZKEPA patent covering REDUCE-IT protocol/results, extending exclusivity to April 2039.
Amarin reports Q4 revenue down 17% to $74.7M; GAAP net loss $5.8M; initiates $50M share repurchase
Total net revenue $74.7M in Q4 2023 vs $90.2M in Q4 2022 (-17%); US net product revenue fell to $64.9M from $88.0M due to generic competition.
Amarin regains Nasdaq minimum bid price compliance; listing continues
Received Nasdaq letter on Jan 25, 2024 confirming regained compliance with minimum bid price rule.
Amarin reports preliminary Q4 rev $72-74M, FY rev $304-306M; announces $50M buyback
Preliminary Q4 2023 total revenue $72-74M (Europe ~$1.5M, US $64-65M, RoW $7-8M).
Amarin receives Nasdaq deficiency notice for bid price below $1.00
ADS closing bid price below $1.00 for 30 consecutive business days triggers deficiency letter.
Amarin Q3 2023: Revenue $66M (-27% YoY), net loss $19.3M; cash flow +$8M
Total net revenue $66.1M, down 27% vs Q3 2022; net loss $19.3M vs $5.1M loss a year ago; diluted EPS loss $0.05.
Amarin Q2 revenue $80M (-15%); net loss narrows to $17.6M; lowers 2023 opex guidance
Total net revenue $80.2M (-15% YoY); net product revenue $65.2M (-31% YoY) due to generic competition.
Amarin appoints Patrick Holt as President and CEO effective July 18, 2023
Patrick Holt appointed President & CEO and Board member; base salary $675,000, eligible for cash incentive.
Amarin reports 23% Q/Q revenue drop to $65M; cuts 30% workforce; appoints new CEO Patrick Holt
Preliminary Q2 product revenue ~$65M, down from $85M Q1; cash $313M (+$9M cash flow including $5M China milestone).
Amarin Q1 revenue $86M (-9% YoY); lowers FY2023 opex guidance to $270-285M
U.S. net product revenue $82.3M (-7% QoQ); generic competition impacts volume and price.
CEO Karim Mikhail resigns effective immediately; company disputes severance claim
Karim Mikhail resigned as President and CEO effective March 27, 2023.
Amarin announces resignation of seven independent directors after Sarissa proxy win
Seven independent non-Sarissa board members resigned effective March 6, 2023.
Amarin Q4 2022 net income $0.9M; revenue down 38% YoY; positive free cash flow $4M
Q4 2022 net product revenue $89.5M, down 38% YoY; U.S. revenue stabilized at $88.0M vs $87.9M in Q3.
Amarin reports preliminary Q4 revenue $88-90M, FY 2022 rev $367-369M, cash $310M
Q4 2022 total net revenue estimated $88-90M; full-year 2022 revenue $367-369M (preliminary, unaudited).
On April 4, 2025, the Board of Directors (the “ Board ”) of Amarin Corporation plc (the “ Company ”) appointed Michael Torok, 46, to the Board to a term commencing on such date.
On March 25, 2025, Mr. Mark DiPaolo notified Amarin Corporation plc (the “Company”) that he has made the decision not to stand for re-election at the 2025 Annual Meeting of Shareholders.
On October 1, 2024, Tom Reilly notified Amarin Corporation plc (the “Company”) of his decision to voluntarily resign as Executive Vice President, Chief Financial Officer and Head of Global HR & Finance, effective October 23, 2024, to pursue another opportunity.
In the interim, the Company’s Vice President, Global Controller, Peter Fishman, will assume the duties as principal financial officer and principal accounting officer of the Company, reporting to the CEO, Aaron Berg, until the Company appoints a permanent replacement.
In addition, Mr. Berg was also appointed as a member of the Company’s board of directors (the “Board”), effective as of the CEO Start Date.
As previously disclosed, on June 3, 2024, Amarin Corporation plc (the “Company”) announced that Aaron Berg was appointed to the role of President and Chief Executive Officer (and principal executive officer) of the Company, effective June 4, 2024
Aaron Berg, who has been serving as the Company’s Executive Vice President, President U.S., has replaced Mr. Holt as President and Chief Executive Officer, effective June 4, 2024 (the “CEO Start Date”).
Mr. Berg has been appointed as a member of the Company’s board of directors (the “Board”), effective as of the CEO Start Date.
On June 3, 2024, Patrick Holt notified Amarin Corporation plc (the “Company”) of his decision to voluntarily resign as President and Chief Executive Officer of the Company, effective immediately.
Patrick Holt was appointed to the role of President and Chief Executive Officer (and principal executive officer) of Amarin, effective July 18, 2023
Mr. Holt was also appointed as a member of the Amarin board of directors (the “ Board ”), effective as of the CEO Start Date.
On July 18, 2023, Amarin appointed Patrick Holt to serve as the Company’s President and Chief Executive Officer (and principal executive officer), and as a member of the Board, effective July 18, 2023.
Max materiality 0.90 · Median 0.65 · Most common event earnings